Lupus Diagnosis via Anti-THEX1 Autoantibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for lupus are inefficient, requiring multiple tests and often resulting in delayed and inaccurate diagnoses due to low specificity and sensitivity, especially when classical markers are absent.
Innovation Solution
Detection of autoantibodies against the protein biomarker THEX1 in biological samples, which correlates strongly with lupus presence and severity, using methods such as immunoassays and protein arrays for improved diagnostic and prognostic capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple classical autoantibody tests (ANA, anti-DNA, anti-Sm, etc.) are used for lupus diagnosis, then sensitivity is improved, but specificity deteriorates due to false positives from infections and other rheumatic diseases
Solution Approach 1:
The patent segments the diagnostic approach by introducing a new specific autoantibody marker (anti-THEX1) that can be tested separately from classical markers. This segmentation allows clinicians to use anti-THEX1 testing specifically when classical markers are absent or inconclusive, thereby improving diagnostic specificity without sacrificing sensitivity through targeted application rather than universal use of multiple tests
Solution Approach 2:
The patent changes the diagnostic parameter by identifying and measuring a new autoantibody target (anti-THEX1) with different immunological properties than classical markers. This new parameter demonstrates superior specificity (94%) compared to classical markers like ANA (57% specificity), allowing for more accurate differentiation of lupus from other conditions while maintaining high sensitivity through the 53% detection rate
2Measurement precision
If multiple differing test results must be integrated for clinical judgement, then diagnostic accuracy is improved, but time to diagnosis deteriorates (average 4 years)
Solution Approach 1:
The patent enables preliminary action by providing a specific anti-THEX1 test that can be performed early in the diagnostic workup, particularly when classical markers are absent. This preliminary testing with a highly specific marker can quickly identify lupus cases that would otherwise require lengthy differential diagnosis, reducing the average 4-year diagnostic delay while maintaining accuracy through targeted application
Solution Approach 2:
The patent extracts the diagnostic function from the complex integration of multiple tests by providing a standalone anti-THEX1 test that can definitively identify lupus in cases where classical markers are absent. This extraction simplifies the diagnostic process by removing the need to integrate multiple differing test results in ambiguous cases, thereby reducing diagnostic time while preserving accuracy through the marker's high specificity
3Adaptability or versatility
If classical markers are absent, then alternative markers are needed to improve diagnostic capability, but no single alternative marker currently provides both high sensitivity and specificity
Solution Approach 1:
The patent changes the diagnostic parameter by introducing anti-THEX1 as a new autoantibody marker with distinct immunological characteristics. This new parameter achieves both high sensitivity (53%) and high specificity (94%), overcoming the limitation of existing alternative markers that cannot simultaneously provide both performance metrics. The marker demonstrates adaptability by being particularly useful in cases where classical markers are absent, while maintaining superior precision through its specific recognition of THEX1 protein
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a specificity of 94% and sensitivity of 53% for diagnosing lupus, with higher autoantibody levels indicating more severe disease, providing a new marker for both diagnosis and monitoring disease activity.
Implementation Method 1
detection of the autoantibody may be performed by immunoassay
Implementation Method 2
using methods such as immunoassays and protein arrays for improved diagnostic and prognostic capabilities
Data Source
AI summary
The present invention relates to an in vitro method for diagnosing lupus in a subject, said method comprising the step of detecting in a biological sample obtained from the subject the autoantibody recognizing the protein biomarker THEX1. More, the invention relates to kits and array useful for carrying out diagnosis methods according to the present invention.